COL.AU

18.72

+1.85%↑

CAR.AU

36.78

-0.14%↓

WOR.AU

14.51

-1.96%↓

RSG.AU

0.67

+3.08%↑

MMS.AU

16.14

+0.75%↑

COL.AU

18.72

+1.85%↑

CAR.AU

36.78

-0.14%↓

WOR.AU

14.51

-1.96%↓

RSG.AU

0.67

+3.08%↑

MMS.AU

16.14

+0.75%↑

COL.AU

18.72

+1.85%↑

CAR.AU

36.78

-0.14%↓

WOR.AU

14.51

-1.96%↓

RSG.AU

0.67

+3.08%↑

MMS.AU

16.14

+0.75%↑

COL.AU

18.72

+1.85%↑

CAR.AU

36.78

-0.14%↓

WOR.AU

14.51

-1.96%↓

RSG.AU

0.67

+3.08%↑

MMS.AU

16.14

+0.75%↑

COL.AU

18.72

+1.85%↑

CAR.AU

36.78

-0.14%↓

WOR.AU

14.51

-1.96%↓

RSG.AU

0.67

+3.08%↑

MMS.AU

16.14

+0.75%↑

Home・Aktien・CSL Ltd

CSL Ltd

Geschlossen

Branche

303.69 0.59

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

303.19

Max

304.27

Schlüsselkennzahlen
By Trading Economics
Einkommen	1.9B
Verkäufe	8.1B
EPS	4.159
Gewinnspanne	23.606

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+6.31 upside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-686M 148B
Vorheriger Eröffnungskurs	303.1
Vorheriger Schlusskurs	303.69

Nachrichtenstimmung

By Acuity

50%

92 / 382 Ranking in Industrials

CSL Ltd Chart

Ähnliche Nachrichten

12. Aug. 2024, 23:23 UTC

Ergebnisse

CSL Annual Profit Rises by 20% on Immunoglobulins Growth -- Update

12. Aug. 2024, 22:49 UTC

Ergebnisse

CSL Annual Profit Rises by 20%, Forecasts Fiscal Year 2025 Underlying Earnings Growth

12. Feb. 2024, 22:16 UTC

Ergebnisse

CSL Says 1st Half Profit Rises, Boosts Dividend -- Update

12. Feb. 2024, 22:00 UTC

Ergebnisse

CSL Says 1st Half Profit Rises, Boosts Dividend

13. Aug. 2024, 00:33 UTC

Market Talk

CSL Profit Outlook Looks Weaker Than Expected -- Market Talk

12. Aug. 2024, 22:34 UTC

Ergebnisse

CSL Annual Profit Rises by 20%, Forecasts FY 2025 Underlying Earnings Growth

12. Aug. 2024, 22:18 UTC

Ergebnisse

CSL Expects FY2025 Revenue Growth of Roughly 5%-7% at Constant Currency

12. Aug. 2024, 22:18 UTC

Ergebnisse

CSL: Conditions for Seqirus Remain Challenging, But Unit Expected to Outperform Market

12. Aug. 2024, 22:17 UTC

Ergebnisse

CSL: Has a Number of Efficiency Initiatives Underway in Plasma Collections, Manufacturing Operations

12. Aug. 2024, 22:16 UTC

Ergebnisse

CSL: Momentum in Behring Seen Underpinned by Strong Patient Demand in Immunoglobulins

12. Aug. 2024, 22:15 UTC

Ergebnisse

CSL: Remains Confident in Medium-Term Double-Digit Earnings Growth Target

12. Aug. 2024, 22:14 UTC

Ergebnisse

CSL: Vifor Continues to Grow Iron Volume in Europe Despite Generic Entrants

12. Aug. 2024, 22:13 UTC

Ergebnisse

CSL Expects FY2025 Underlying Profit Up Between 10%-13% on Constant Currency Basis

12. Aug. 2024, 22:13 UTC

Ergebnisse

CSL Expects FY2025 Underlying Profit Between US$3.2 Billion-US$3.3 Billion

12. Aug. 2024, 22:11 UTC

Ergebnisse

CSL: Outlook for Behring Positive But Competitive Pressures Increased Recently

12. Aug. 2024, 22:10 UTC

Ergebnisse

CSL FY Underlying Profit Up 15% on Constant Currency Basis to US$3.01 Billion

12. Aug. 2024, 22:09 UTC

Ergebnisse

CSL FY Revenue US$14.80 Billion, Up 11% On-Year

12. Aug. 2024, 22:08 UTC

Ergebnisse

CSL FY Underlying Profit US$2.91 Billion, Up 11% On-Year

12. Aug. 2024, 22:07 UTC

Ergebnisse

CSL FY Net Profit US$2.64 Billion, Up 20% On-Year

12. Aug. 2024, 22:07 UTC

Ergebnisse

CSL Final Dividend US$1.45/Share

13. Feb. 2024, 01:50 UTC

Market Talk

Ergebnisse

CSL Still Confident on Long-Term Value at Vifor Business -- Market Talk

13. Feb. 2024, 00:39 UTC

Market Talk

Ergebnisse

UBS Sees Mixed Bag in CSL's Half-Year Results -- Market Talk

12. Feb. 2024, 22:01 UTC

Ergebnisse

CSL Says 1H Profit Rises, Boosts Dividend -- Update

12. Feb. 2024, 21:45 UTC

Peer-Vergleich

Kursveränderung

CSL Ltd Prognose

Kursziel

By TipRanks

6.31% Vorteil

12-Monats-Prognose

Durchschnitt 323.182 AUD 6.31%

Hoch 352 AUD

Tief 278 AUD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für CSL Ltd – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

12 ratings

Buy

Halten

Sell

Basierend auf 12 Analysten, die in den letzten 3 Monaten Aktienbewertungen für CSL Ltd – Dist abgegeben haben.

Stimmung

By Acuity

92 / 382 Ranking in

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über CSL Ltd

CSL Limited is an Australia-based biotechnology company. The Company is engaged in developing and delivering biotherapies and influenza vaccines that treat people with serious diseases and chronic medical conditions. It offers treatments for people who are living with conditions in immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The Company operates through two segments: CSL Behring and Seqirus. CSL Behring manufactures, markets, and develops plasma therapies (plasma products and recombinants), conducts early-stage research on plasma and non-plasma therapies, excluding influenza, receives license and royalty income from the commercialization of intellectual property and undertakes the administrative and corporate function required to support the Company. Seqirus segment manufactures and distributes non-plasma biotherapeutic products and develops influenza related products. Its products include PRIVIGEN, IDELVION and AFSTYLA.